Clinical Trial Update: PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine [Phase 1]

View source ↗

Summary

Phase 1 clinical trial of PA83-FhCMB plant-derived recombinant protective antigen (rPA) anthrax vaccine completed; the sponsor reports the study status as compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anthrax

Drugs mentioned

• PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine (recombinant protective antigen (rPA) vaccine)

Snippet

Sponsor: Fraunhofer, Center for Molecular Biotechnology | Conditions: Anthrax | Phase 1 | Status: COMPLETED